Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
- Address
- lock Available on a paid plan
Ophthalmology and Eye Diseases
At Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, clinical research in Eye Diseases focuses on common and vision-threatening conditions, with studies aimed at improving treatment outcomes and post-surgical recovery.
- Neovascular Age-Related Macular Degeneration
- Thyroid Eye Disease
- Postoperative inflammation after cataract surgery
This area includes trials testing new therapies and evaluating how to better control inflammation and preserve visual function.
Oncology and Hematologic Malignancies
A major part of the site’s research portfolio covers Neoplasms and blood cancers, with studies designed to assess new cancer treatments, compare them with standard care, and improve disease control.
- Breast Cancer
- Multiple Myeloma
- Acute Myeloid Leukemia
- Head and Neck Squamous Cell Carcinoma
These trials explore both targeted and immunotherapy-based approaches, aiming to extend survival and refine treatment strategies for difficult-to-treat cancers.
Cardiovascular and Metabolic Research
The site conducts extensive studies in Cardiovascular Diseases and Metabolic Disorders, reflecting a strong interest in prevention, risk reduction, and long-term disease management.
- Atherosclerotic Cardiovascular Disease
- Atrial Fibrillation
- Hypertension
- Type 2 Diabetes Mellitus
- Obesity
Research here often evaluates new therapies for lowering cardiovascular risk, improving blood sugar control, and supporting healthier weight and lipid profiles.
Liver and Digestive System Disorders
A substantial share of trials at this hospital address Digestive System Diseases, especially chronic liver conditions and inflammatory bowel disease, with an emphasis on symptom relief and slowing progression.
- Primary Biliary Cholangitis
- Non-Alcoholic Steatohepatitis
- Chronic Hepatitis B
- Ulcerative Colitis
- Crohn's disease
The research includes studies of new treatments for liver inflammation, fibrosis, cholestatic symptoms, and bowel inflammation.
Neurology, Immunology, and Autoimmune Disease
Clinical trials in Nervous System Diseases and Immune System Diseases investigate conditions that affect movement, memory, and immune regulation, with a focus on symptom control and disease slowing.
- Alzheimer's Disease
- Amyotrophic Lateral Sclerosis
- Multiple Sclerosis
- Generalized Myasthenia Gravis
- Sjögren’s Syndrome
The studies aim to test new therapies, improve patient-reported outcomes, and better understand autoimmune and neurodegenerative disease activity.
Respiratory, Infectious, and Inflammatory Conditions
Research at the site also spans Respiratory Tract Diseases, Virus Diseases, and inflammatory disorders, supporting efforts to improve infection control and long-term symptom management.
- Asthma
- Bronchiectasis
- Pneumonia
- Respiratory Syncytial Virus Infections
- HIV Infections
These trials are designed to evaluate treatment effectiveness, reduce exacerbations, and strengthen care for patients with chronic or recurrent respiratory and infectious diseases.
Rare Diseases, Genetic Disorders, and Other Specialized Studies
The portfolio at Policlinico Paolo Giaccone also includes specialized research in rare and complex conditions, combining Analytical, Diagnostic and Therapeutic Techniques with targeted disease-specific studies.
- Primary Myelofibrosis
- Familial Hypercholesterolemia
- Congenital Adrenal Hyperplasia
- Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
- Neuroendocrine tumors
This work supports earlier diagnosis, better risk assessment, and the development of more precise therapies for uncommon and hard-to-treat diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 24 therapeutic areas and 15 of 269 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 252 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 55 by active trials.
- 1Novo Nordisk A/S5active
lock +54 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S10trials
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
lock Showing 1 of 185 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 269 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 8 | Unknown | 2022-04-19 | 2025-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.